ins-5 Antibody

What is INSL5 and what are its key structural characteristics?

INSL5 (Insulin-like peptide 5) is a secreted protein belonging to the Insulin protein family. In humans, the canonical form consists of 135 amino acid residues with a molecular mass of approximately 15.3 kDa . It exists as a peptide hormone structurally related to insulin, containing characteristic disulfide bonds that are essential for its biological activity. INSL5 is primarily expressed in the rectum with lower expression levels detected in the uterus and both ascending and descending regions of the colon . Like other members of the insulin/relaxin family, INSL5 likely functions through specific receptor-mediated pathways, in this case primarily through its cognate receptor RXFP4 .

How is INSL5 expression distributed across different tissues?

INSL5 demonstrates a tissue-specific expression pattern with highest expression in the digestive system, particularly in the rectum . Lower but significant expression occurs in the uterus and colon segments. In immune tissues, expression has been detected in the thymus, where it shows age-dependent regulation, with highest expression observed in younger subjects . Through comprehensive data mining approaches, researchers have determined that INSL5 is specifically expressed in certain immune cell populations, including double-positive (DP) and double-negative (DN) thymocytes, cortical thymic epithelial cells (cTECs), intestinal epithelial lymphocytes (IELs), and select CD4+ T-cell subsets . This distribution pattern suggests specialized roles in gut function and potentially in immune system development and regulation.

What is the main function of INSL5 in physiological systems?

INSL5 is believed to serve multiple physiological functions, primarily in gut contractility regulation and potentially in thymic development and immune system modulation . Recent research has demonstrated that INSL5 can influence metabolic parameters through insulinotropic effects, evidenced by elevations in GLP-1, C-peptide, and insulin levels following INSL5 administration in experimental models . Additionally, INSL5 appears to play a novel role in immune signaling, as it can alter cytokine profiles in the peripheral immune system, particularly affecting cytokines involved in macrophage proliferation (MIP-2, G-CSF, M-CSF) and homeostatic processes (IL-7, IL-15) . The INSL5-RXFP4 axis may thus represent a previously unrecognized communication pathway between metabolic and immune systems.

What types of INSL5 antibodies are available for research applications?

Researchers can select from various types of INSL5 antibodies optimized for different experimental applications. These primarily include:

When selecting an INSL5 antibody, researchers should consider the specific epitope targeted (often middle region or other conserved domains), the host species in which the antibody was produced, conjugation status (unconjugated or tagged with fluorescent/enzyme labels), and validated applications . Antibody validation is critical, as target specificity varies significantly among commercially available products.

How should researchers validate INSL5 antibody specificity before experimental use?

Validation of INSL5 antibody specificity is essential for obtaining reliable experimental results. A comprehensive validation protocol should include:

• Positive and negative control tissues: Testing antibody reactivity in tissues known to express high levels of INSL5 (rectum, colon) versus tissues with minimal expression

• Western blot analysis: Confirming detection of a band at the expected molecular weight (~15.3 kDa)

• Peptide competition assay: Pre-incubating the antibody with excess INSL5 peptide should abolish specific binding

• Knockout/knockdown controls: Testing on samples from INSL5 knockout models or cells treated with INSL5-specific siRNA

• Cross-reactivity assessment: Evaluating potential cross-reactivity with other insulin family members, particularly in evolutionary studies

Similar to methods used for IgLON5 antibody confirmation, cell-based assays (CBAs) using cells transfected with INSL5 complementary DNA may provide definitive validation of antibody specificity . Comprehensive validation ensures experimental reproducibility and accurate interpretation of results.

What are the optimal protocols for using INSL5 antibodies in Western blot applications?

For successful Western blot detection of INSL5, researchers should consider the following methodological recommendations:

• Sample preparation:

  • Fresh tissue homogenization in RIPA buffer supplemented with protease inhibitors

  • Sonication for complete lysis of membrane structures

  • Centrifugation at 14,000g for 15 minutes to remove debris

• Electrophoresis conditions:

  • 12-15% SDS-PAGE gels to accommodate the 15.3 kDa protein size

  • Include reducing conditions (β-mercaptoethanol) to disrupt disulfide bonds

• Transfer and detection:

  • PVDF membranes with 0.2 μm pore size are recommended for small proteins

  • Blocking in 5% non-fat milk or BSA in TBST for 1 hour

  • Primary antibody incubation at optimized dilution (typically 1:500-1:2000) overnight at 4°C

  • HRP-conjugated secondary antibody and ECL detection system

• Controls:

  • Include positive control (rectum tissue lysate)

  • Pre-absorption control with immunizing peptide

  • Loading control (β-actin or GAPDH)

Expected results include detection of INSL5 at approximately 15.3 kDa, with potential detection of precursor forms at higher molecular weights depending on tissue processing and antibody specificity .

How can INSL5 antibodies be effectively utilized in immunohistochemistry and immunofluorescence?

For optimal immunohistochemical and immunofluorescence detection of INSL5:

• Tissue preparation:

  • Fresh frozen sections (8-10 μm) or formalin-fixed paraffin-embedded (FFPE) sections (4-6 μm)

  • For FFPE tissues, antigen retrieval is critical (citrate buffer pH 6.0, 95°C for 20 minutes)

  • Permeabilization with 0.2% Triton X-100 for intracellular epitopes

• Staining protocol:

  • Block with 5-10% normal serum from secondary antibody host species

  • Primary antibody incubation at optimized dilution (typically 1:50-1:200) for 1-2 hours at room temperature or overnight at 4°C

  • For indirect immunofluorescence, use fluorophore-conjugated secondary antibodies

  • For IHC, employ biotin-streptavidin or polymer-based detection systems

• Counterstaining and mounting:

  • Nuclear counterstain (DAPI for IF, hematoxylin for IHC)

  • Mounting in appropriate medium (anti-fade for IF, permanent mounting for IHC)

• Controls:

  • Include positive control tissues (rectum, colon)

  • Perform secondary-only controls to assess background

  • Consider dual staining with neuroendocrine markers for co-localization studies

Expected staining patterns include cytoplasmic and potentially secretory granule localization in enteroendocrine cells of the rectum and colon, with possible detection in specific immune cell populations in thymus and gut-associated lymphoid tissues .

What approaches can be used to study INSL5-RXFP4 signaling in immune cell populations?

Investigating INSL5-RXFP4 signaling in immune cells requires specialized methodological approaches:

• Expression analysis of RXFP4 in immune cells:

  • qRT-PCR to quantify RXFP4 mRNA in isolated immune cell subsets

  • Flow cytometry using validated RXFP4 antibodies for protein-level detection

  • Single-cell RNA sequencing to identify specific immune cell populations expressing RXFP4

• Functional assays for INSL5 effects on immune cells:

  • Cell proliferation assays following INSL5 treatment (as demonstrated with ANA-1 macrophages)

  • Cytokine expression analysis using qRT-PCR or multiplex protein assays

  • Intracellular signaling assessment (phosphorylation of downstream effectors)

  • Migration/chemotaxis assays to assess INSL5 chemotactic properties

• In vivo approaches:

  • INSL5 administration to experimental animals with assessment of systemic and tissue-specific immune parameters

  • Analysis of splenic T-cell populations by flow cytometry following INSL5 injection

  • Conditional knockout models targeting INSL5 or RXFP4 in specific immune cell lineages

Recent research has demonstrated that bone marrow-derived dendritic cells (BMDCs) express RXFP4 during differentiation, with expression increasing from day 1 to days 3 and 7, and showing six-fold higher expression in splenic DCs compared to non-DC fractions . This suggests that experimental approaches targeting dendritic cell functions may be particularly informative.

How does INSL5 influence cytokine production and immune cell function?

INSL5 exhibits complex modulatory effects on cytokine production and immune cell function. Experimental evidence indicates:

These findings suggest that INSL5 may function as an immunomodulatory peptide with predominantly anti-inflammatory properties, potentially representing a novel link between metabolic and immune systems.

What is the relationship between INSL5 and metabolic signaling in immune contexts?

The interplay between INSL5 and metabolic regulation in immune contexts represents an emerging area of research:

• INSL5 effects on metabolic peptides:

  • Significantly elevated blood GLP-1 at 6 and 24 hours post-injection

  • Increased C-peptide, insulin, and glucagon at 24 hours post-injection

  • Elevated PP at 6 hours and PYY and Amylin at 24 hours post-injection

• Potential mechanism of integration:

  • INSL5 produced by intestinal L-cells may serve as a communication signal between gut and immune system

  • Expression of RXFP4 on specific immune cell populations enables direct sensing of metabolic signals

  • Altered energy metabolism in immune cells following INSL5 stimulation may influence inflammatory responses

• Methodological approaches for investigation:

  • Combined metabolic and immunological profiling following INSL5 administration

  • In vitro assessment of metabolic parameters (oxygen consumption, glycolysis) in immune cells treated with INSL5

  • Analysis of immune responses in metabolic disease models with altered INSL5-RXFP4 signaling

This bidirectional relationship suggests that INSL5 may function as part of an intricate network coordinating gut function, metabolic status, and immune responses, with potential implications for inflammatory and metabolic disorders.

How can transcription factor analysis inform understanding of INSL5 expression regulation?

Advanced transcription factor (TF) analysis provides critical insights into INSL5 expression regulation:

• Phylogenetic footprinting results:

  • Strong evidence for regulation by immune-related transcription factors

  • STAT family members (STAT1, STAT4, STAT5a/5b) implicated in INSL5 regulation

  • FOXP3, a master regulator of T-cell development, may influence INSL5 expression

  • TCF-1 and NF-AT, enhancers of thymus-specific gene expression, potentially regulate INSL5

• Methodological approaches for TF analysis:

  • Chromatin immunoprecipitation (ChIP) to confirm binding of predicted TFs to INSL5 promoter

  • Reporter gene assays with wild-type and mutated INSL5 promoter constructs

  • CRISPR/Cas9-mediated deletion or mutation of predicted TF binding sites

  • Analysis of INSL5 expression following pharmacological modulation of TF activity

• Functional implications:

  • JAK/STAT signaling may link cytokine signals to INSL5 expression

  • Developmental regulation in thymus may be controlled by T-cell specific TFs

  • Inflammatory signals could modulate INSL5 expression through NF-κB pathways

This complex transcriptional regulation suggests that INSL5 expression is integrated into immune developmental and functional networks, providing mechanisms for context-specific expression in different physiological and pathological states.

How do detection methods for INSL5 antibodies compare with IL-5 antibody applications?

While both targeting molecules with "IL-5" in their names, INSL5 (Insulin-like peptide 5) and IL-5 (Interleukin 5) antibodies require distinct optimization approaches:

Methods for IL-5 detection in human peripheral blood lymphocytes typically employ immunofluorescence techniques with specific monoclonal antibodies (such as MAB605) at defined concentrations (e.g., 5 μg/mL) with incubation for 3 hours at room temperature . Unlike INSL5, IL-5 detection often focuses on intracellular cytokine staining and flow cytometry applications in activated immune cells.

What methodological parallels exist between IgLON5 and INSL5 antibody validation?

Despite targeting unrelated molecules, validation approaches for IgLON5 and INSL5 antibodies share important methodological principles:

• Confirmation of specificity:

  • Both require cell-based assays (CBAs) to confirm target specificity

  • For IgLON5, CBAs use human embryonic kidney 293 cells transfected with IgLON5 complementary DNA

  • Similar approaches could validate INSL5 antibodies using INSL5-transfected cell lines

• Tissue substrate testing:

  • IgLON5 antibody validation employs composite substrate testing on multiple tissues (mouse hippocampus, cerebral cortex, cerebellum, etc.)

  • INSL5 antibody validation similarly benefits from testing on multiple tissues with known expression patterns

• Sample processing procedures:

  • Fixed tissue preparations (1% formalin for IgLON5 CBA)

  • Standardized dilution protocols (1:10 dilution for serum, neat for CSF in IgLON5 testing)

  • Secondary antibody controls (fluorescein isothiocyanate–conjugated goat antihuman IgG)

These methodological parallels highlight the importance of rigorous validation procedures for research antibodies regardless of target, with cell-based confirmation assays representing a gold standard approach for definitive specificity validation.

What are common technical challenges in INSL5 antibody applications and their solutions?

Researchers working with INSL5 antibodies may encounter several technical challenges:

• Low signal intensity in Western blots:

  • Challenge: INSL5's relatively low abundance in many tissues

  • Solution: Enrich samples through immunoprecipitation; use high-sensitivity detection systems; optimize protein loading (40-60 μg per lane); consider enhanced chemiluminescence substrate with extended exposure times

• Non-specific binding in immunohistochemistry:

  • Challenge: Cross-reactivity with other insulin family members

  • Solution: Increase blocking duration (2-3 hours); use concentration-matched isotype control antibodies; perform peptide competition controls; optimize antibody dilution through titration experiments

• Variable results across different tissue preparations:

  • Challenge: Epitope sensitivity to fixation conditions

  • Solution: Compare multiple fixation methods (formalin, paraformaldehyde, methanol); optimize antigen retrieval protocols; consider using fresh frozen tissues for sensitive epitopes

• Inconsistent results in functional studies:

  • Challenge: Variable activity of recombinant INSL5 preparations

  • Solution: Validate biological activity of INSL5 preparations through receptor binding assays; use multiple concentrations (10-1000 nM range) in cell-based experiments; include positive controls for signaling pathways

• Difficult detection in immune cells:

  • Challenge: Low expression levels in specific immune subpopulations

  • Solution: Use cell enrichment techniques before analysis; employ tyramide signal amplification for IF/IHC; consider RNAscope for mRNA detection; optimize flow cytometry protocols with attention to permeabilization conditions

How can researchers design experiments to investigate INSL5's role in neuroendocrine-immune interactions?

Investigating INSL5's role at the neuroendocrine-immune interface requires sophisticated experimental design:

• In vitro co-culture systems:

  • Primary enteroendocrine cells (or L-cell models) with immune cell populations

  • Assessment of bidirectional signaling through cytokine/receptor expression analysis

  • Transwell systems to distinguish contact-dependent versus soluble mediator effects

• Ex vivo tissue explant approaches:

  • Precision-cut tissue slices from colon/rectum maintaining cellular architecture

  • Treatment with recombinant INSL5 or INSL5 neutralizing antibodies

  • Analysis of immune cell recruitment, activation, and function

• In vivo models with tissue-specific manipulation:

  • Conditional knockout of INSL5 in enteroendocrine cells versus immune cell populations

  • Chemogenetic or optogenetic activation of INSL5-producing cells

  • Assessment of immune responses during homeostasis and inflammatory challenges

• Multi-parameter analysis techniques:

  • Single-cell RNA sequencing of intestinal tissues to identify INSL5+ and RXFP4+ populations

  • Spatial transcriptomics to map expression patterns relative to lymphoid structures

  • Multiplex cytokine profiling following manipulation of INSL5-RXFP4 axis

These approaches can help elucidate whether INSL5 functions primarily as an enteroendocrine signal that secondarily influences immune function, or whether it represents a dedicated communication pathway in neuroendocrine-immune crosstalk.